CeptarisCeptaris CompanyCeptaris Investigational DrugCeptaris NewsCeptaris Contact Us  
       
       
   
 
 
     
  Overview  
  Management  
  Board of Directors  
  Investors  
     
 


Stephen Tullman | Chairman and Chief Executive Officer
Tim Henkel, M.D., Ph.D.
| Executive Vice President, Head of Research and Development
Doug Gessl
| Chief Operating Officer and Chief Financial Officer
H. Jeffrey Wilkins, M.D.
| Chief Medical Officer
Kamil Ali-Jackson
| Chief Legal Officer
Evan G. Dick, Ph.D.
| Senior Vice President of Business Development
Kelly Copeland
| Vice President of Product Strategy
Jeffrey Shaver, Ph.D.
| Vice President of Project Management and Operations
Lisa Wittmer, Ph.D.
| Vice President of Regulatory Affairs


Stephen Tullman, Chairman and Chief Executive Officer

Joining Ceptaris in May 2011, Mr. Tullman brings more than 21 years of biopharmaceutical global commercialization and drug development experience. Mr. Tullman formerly served as the Executive Chairman of Vicept Therapeutics, which was acquired by Allergan Therapeutics in July 2011, and has co-founded and led numerous companies: Ception Therapeutics, a biologics company (acquired by Cephalon); Trigenesis Therapeutics, a dermatology company (acquired by Dr. Reddy’s Laboratories); and Cutix Pharmaceuticals, a privately held dermatology company. He also served on the Board of Directors for Euromed, a wound care company. Mr. Tullman started his career at GlaxoSmithKline and held positions of increasing responsibility in finance, sales, marketing, and research and development. Mr. Tullman earned a B.S. from Rutgers University in New Jersey.

Tim Henkel, M.D., Ph.D., Executive Vice President, Head of Research and Development

Dr. Henkel has spent more than 15 years in the biopharmaceutical industry developing anti-inflammatory, antibacterial, antifungal, and antiviral drugs. Prior to joining Ceptaris, Dr. Henkel was Executive Vice President of Research and Development at Ception Therapeutics, a biologics company (acquired by Cephalon). He also served as Chief Medical Officer at Vicuron Pharmaceuticals (acquired by Pfizer) and as a Vice President of GlaxoSmithKline. Dr. Henkel was Assistant Professor of Internal Medicine and Infectious Diseases at Washington University in St. Louis where he earned his board certifications in both Internal Medicine and Infectious Diseases. He earned his M.D. and Ph.D. in immunology from Washington University in St. Louis, and his B.S. in Chemistry and Biology from Rhodes College.

Doug Gessl, Chief Operating Officer and Chief Financial Officer

Prior to joining Ceptaris, Mr. Gessl was Chief Financial Officer and Senior Vice President of Ception Therapeutics, a biologics company (acquired by Cephalon). Previously, Mr. Gessl was a Senior Vice President with Einhorn Associates and acted as financial advisor and lead negotiator for Fulcrum Pharmaceuticals, Inc., a legacy company to Ception, in its Series A financings. Mr. Gessl’s prior experience covers approximately 20 years completing merger and acquisition transactions, public and private capital and structured finance offerings for clients, as well as roles in international strategic planning and consulting. Mr. Gessl received his M.B.A. from the University of Chicago and a B.B.A. in Finance, Investments and Banking from the University of Wisconsin.

H. Jeffrey Wilkins, M.D., Chief Medical Officer

Dr. Wilkins has 16 years of clinical research experience. Prior to joining Ceptaris, he served as Vice President of Worldwide Clinical Development: Oncology and Immunology at Cephalon. Before joining Cephalon, he was Senior Vice President of Clinical Development with Ception Therapeutics, a biologics company (acquired by Cephalon). He entered the pharmaceutical industry joining GlaxoSmithKline after 10 years as a family medicine physician. Dr. Wilkins was co-founder and Chief Executive Officer of TriValley Primary Care, a large multi-center primary group in northern Bucks and Montgomery Counties in Pennsylvania. Dr. Wilkins earned his M.D. from Temple University and a B.S. from Bucknell University.

Kamil Ali-Jackson, Chief Legal Officer

Kamil Ali-Jackson has more than 25 years of experience as in-house and external legal counsel in the life-sciences industry. Prior to joining Ceptaris, she served as General Counsel and Secretary, Ception Therapeutics, Inc.; Vice President, Legal, and Associate General Counsel, Dr. Reddy's Laboratories, Inc.; Vice President and Associate General Counsel, Endo Pharmaceuticals, Inc.; legal counsel for the vaccine and human health divisions of Merck & Co., Inc. and a corporate licensing executive for Merck & Co., Inc. In these roles, she handled various domestic and international commercial transactions, FDA regulatory, privacy, securities and corporate governance matters, and commercial and product liability litigation. Kamil has an undergraduate degree from Princeton University and a J.D. from Harvard Law School.

Evan Dick, Ph.D., Senior Vice President of Business Development

Dr. Dick brings more than 28 years of pharmaceutical and biotechnology experience to Ceptaris, most recently having served as Senior Vice President of Discovery Medicine and Operations at Ception Therapeutics, a biologics company (acquired by Cephalon). He has held positions with Fulcrum Pharmaceuticals, Inc., (a legacy company to
Ception), Kereos, Inc., MedStrategy, Inc., Cytotaxis, Inc., and G.D. Searle & Company. Dr. Dick is also a former member of the Departments of Ophthalmology and Pharmacology at the Washington University School of Medicine. He earned a B.S. from Cornell University and Ph.D. from SUNY Buffalo.

Kelly Copeland, Vice President of Product Strategy

Ms. Copeland has more than 15 years of experience working in the healthcare industry. Before joining Ceptaris, Ms. Copeland was the Vice President of Business Development and Product Strategy for Ception Therapeutics, a biologics company (acquired by Cephalon). She spent six years with GlaxoSmithKline providing commercial strategy and product development support. Prior to GlaxoSmithKline, Ms. Copeland held positions at Henry Ford Health System and Provider Partnerships, Inc. Ms. Copeland earned her M.S. in Health Services Administration and a B.S. from the University of Michigan. Additionally, she completed a post-graduate fellowship with Henry Ford Health System.

Jeffrey Shaver, Ph.D., Vice President of Project Management and Operations

Prior to joining Ceptaris, Dr. Shaver gained extensive experience in the pharmaceutical industry, previously serving as Vice President of Project Management, Alliances and Information Technology for Ception Therapeutics, a biologics company (acquired by Cephalon). He has held positions with Dr. Reddy’s Laboratories, Ltd and GlaxoSmithKline. Prior to entering the pharmaceutical industry, Dr. Shaver also served in positions of increasing responsibility in engineering management, project management and policy in the United States Air Force. Dr. Shaver is a Distinguished Graduate from the United States Air Force Academy, and earned a M.S. from Purdue University and Ph.D. from the Massachusetts Institute of Technology.

Lisa Wittmer, Ph.D., Vice President of Regulatory Affairs

Dr. Wittmer has held scientific, research and development, regulatory affairs and management positions for more than 15 years in the biopharmaceutical industry. Prior to her current position, Dr. Wittmer was Vice President and General Manager of the Emerging Products Business Unit at Shire Pharmaceuticals where she was responsible for managing the investment into and programs associated with the company's pre-proof-of-concept pipeline. Prior to this role, she was a senior leader in Global Regulatory Affairs at Shire Pharmaceuticals. Dr. Wittmer earned a B.S. in Chemistry from the University of Detroit, a M.S. in Chemistry and a Ph.D. in Neuropharmacology and Molecular Biophysics from Washington University, and completed a Howard Hughes Fellowship in Neurobiology at Duke University.

 
   
     
 
   
   
   
   
         
print page